On this basis, after adding CAR to activate CHRM1, it was found that the previous inhibitory effect was not significantly restored, suggesting that high expression of Atg5 could be a contributing factor in the early and malignant progression of malignant tumors. This evidence concerns the gene ATG5 and cancer.